USFDA issues 3 observations for Granules India Gagillapur facility
Advertisement
Hyderabad: Granules India has recently announced that US Food and Drug Administration (USFDA) has concluded Pre-Approval Inspection (PAI) with three observations at the company's Gagillapur facility.
The facility was inspected from 9th January 2023 to 13th January 2023.
"Please be informed that Company’s Gagillapur facility located at Hyderabad, Telangana, India has completed the US FDA’s Pre-Approval Inspection (PAI) from 9th January 2023 to 13th January 2023 with 3(three) observations, and the Company will respond to these observations within the stipulated time period," Granules stated in BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.